Tumor microenvironment modifications induced by afatinib in squamous cell carcinoma of the head and neck - a window-of-opportunity study (EORTC90111-24111).
Simon P BeyaertAxelle E LoriotNicolas D G HuygheRose M GoebbelsAntonella MendolaAnne-Sophie GovaertsCatherine FortpiedPamela BaldinLisa F LicitraYassine LalamiPaul M J ClementJean-Pascal H MachielsSandra SchmitzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Short-term treatment with afatinib in primary HNSCC induces CD3+ and CD8+ tumor infiltration and, in some patients, EMT and CAFs activation. These results open perspectives to overcome resistance mechanisms to anti-HER therapy and to potentiate the activity of immune checkpoint inhibitors.
Keyphrases
- squamous cell carcinoma
- end stage renal disease
- ejection fraction
- newly diagnosed
- epidermal growth factor receptor
- chronic kidney disease
- epithelial mesenchymal transition
- prognostic factors
- stem cells
- patient reported outcomes
- nk cells
- signaling pathway
- bone marrow
- lymph node metastasis
- rectal cancer
- replacement therapy
- cell therapy